The use of CD34-specific agents, such as aptamers (Apts), to deliver Toc directly to these cells may enhance treatment efficacy by reducing inflammation and fibrosis, ultimately improving clinical outcomes in patients with TAO. Here, CD34 is linked to thromboangiitis obliterans.